Pharma and Biotech
Period Ending | Period | Revenue (£m) | Pre-tax (£m) | EPS | Dividend |
---|---|---|---|---|---|
31-Dec-24 | Q1 | 17.72 | (7.07) | (0.98)p | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-20 | 105.57 | (22.57) | (3.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-21 | 125.06 | (9.18) | (1.93)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-22 | 157.71 | (21.38) | (4.34)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-23 | 103.96 | (24.70) | (3.21)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-24 | 90.36 | (45.92) | (5.99)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-25 | 82.60 | 1.40 | 13.71p | 1.7 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 86.25 | 10.85 | 1.20p | 19.8 | n/a | -91% | n/a | 0.0% |
30-Sep-27 | 94.45 | 12.20 | 1.60p | 14.9 | 0.4 | +33% | n/a | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
5 Yr High | 5 Yr Low | 5 Yr Avg | Curr / Avg | |
---|---|---|---|---|
Latest | n/a | n/a | n/a | 0 |
Find out about IFRS and how this affects the financial infomation for all UK companies.
Currency | UK Pounds |
Share Price | 23.80p |
Change Today | 1.80p |
% Change | 8.18 % |
52 Week High | 45.85p |
52 Week Low | 17.70p |
Volume | 2,445,829 |
Shares Issued | 741.51m |
Market Cap | £176.48m |
Beta | 0.02 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 1 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
13:13 | 4,131 @ 23.80p |
13:13 | 55,387 @ 23.80p |
13:13 | 132,113 @ 23.80p |
12:36 | 33,333 @ 23.80p |
11:32 | 30,000 @ 23.75p |
CFO | Septima Maguire |
CEO | Trond Williksen |
Chair | Tripp Lane |
You are here: research